Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 7/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.47 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667267 | 1.00 | LPAR1 (0.53) | LPAR1LPAR3ALDH1A1CNR1CNR2 | |
| SCHEMBL10566866 | 0.93 | LPAR1 (0.60) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL10562812 | 0.93 | LPAR1 (0.60) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL2672057 | 0.93 | LPAR1 (0.60) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL753952 | 0.92 | LPAR1 (0.58) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| SCHEMBL8902468 | 0.88 | ALDH1A1 (0.51) | LPAR1LPAR3ALDH1A1CNR1CNR2 | |
| SCHEMBL4428224 | 0.87 | PRKCE (0.56) | LPAR1LPAR3CNR1CNR2LPAR2 | |
| SCHEMBL10563457 | 0.84 | LPAR1 (0.53) | LPAR1LPAR3ALDH1A1LPAR2LPAR5 | |
| SCHEMBL17291865 | 0.83 | LPAR1 (0.47) | LPAR1LPAR3LPAR2LPAR5USP2 | |
| Ammonia Solution, Strong SCHEMBL6373587 | 0.83 | LPAR1 (0.60) | LPAR1LPAR3LPAR2LPAR5USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7811988-B2 | Lipid mixtures for synthetic surfactants | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-10-12 | — | — | US | claimed |
| EP-1628634-B1 | NOVEL LIPID MIXTURES FOR SYNTHETIC SURFACTANTS | CHIESI FARMA SPA (IT) | 2009-12-23 | — | — | EP | claimed |
| US-20080045449-A1 | A lipid mixture for synthetic surfactants comprising >40% by weight of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and >10% of polyunsaturated phospholipids; treatment of surfactant deficiencies like infant respiratory distress syndrome (RDS); rheology; low surface tension; fast spreading | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-02-21 | — | — | US | claimed |
| EP-3727418-B1 | SURFACTANT FORMULATIONS FOR INHALATION | MERZ PHARMACEUTICALS LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3474832-B1 | SURFACTANT FORMULATIONS FOR INHALATION | MERZ PHARMACEUTICALS LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250288516-A1 | Surfactant Formulations for Inhalation | MERZ PHARMACEUTICALS LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250262150-A1 | Surfactant Formulations for Inhalation | MERZ PHARMACEUTICALS LLC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20240016823-A1 | SURFACTANT FORMULATIONS FOR INHALATION | MERZ PHARMACEUTICALS, LLC | 2024-01-18 | — | — | US | disclosed |
| CN-116355917-B | Varicella-zoster virus mRNA vaccine and application thereof | 上海臻上医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-116747323-A | Microneedle injection mRNA reagent with high drug loading rate and application thereof | 上海臻上医药科技有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116355917-A | Varicella-zoster virus mRNA vaccine and application thereof | 上海臻上医药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-7592469-B2 | Lipid-analogous phosphoric acid triesters | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20080045449-A1 | A lipid mixture for synthetic surfactants comprising >40% by weight of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and >10% of polyunsaturated phospholipids; treatment of surfactant deficiencies like infant respiratory distress syndrome (RDS); rheology; low surface tension; fast spreading | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-02-21 | — | — | US | disclosed |
| EP-0968206-B8 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1628634-A1 | NOVEL LIPID MIXTURES FOR SYNTHETIC SURFACTANTS | CHIESI FARMACEUTICI S.p.A. (IT) | 2006-03-01 | — | — | EP | disclosed |
| US-20060039963-A1 | Lipid-analogo phosphoric acid triesters | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2006-02-23 | — | — | US | disclosed |
| WO-2004105726-A1 | NOVEL LIPID MIXTURES FOR SYNTHETIC SURFACTANTS | CHIESI FARMACEUTICI S.P.A. (IT) | 2004-12-09 | — | — | WO | disclosed |
| EP-1481665-A1 | Novel lipid mixtures for synthetic surfactants | CHIESI FARMACEUTICI S.p.A. (IT) | 2004-12-01 | — | — | EP | disclosed |
| EP-0968206-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998037079-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039963-A1 | Lipid-analogo phosphoric acid triesters | PHOSPHO1, LIPC, LIPA | LPAR1 22/4885LPAR3 45/4885ALDH1A1 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.